Hematologic responses in patients with aplastic anemia treated with deferasirox: a post hoc analysis from the EPIC study
- 12 April 2013
- journal article
- clinical trial
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 98 (7) , 1045-1048
Abstract
Reports are emerging of hematologic responses associated with iron chelation therapy; however, studies are limited in aplastic anemia patients. Deferasirox reduced iron overload in aplastic anemia patients enrolled in the EPIC (Evaluation of Patients’ Iron Chelation with Exjade®) study (n=116). A post hoc analysis of hematologic responses was conducted on 72 patients with evaluable hematologic parameters (according to UK guideline criteria), 24 of whom received deferasirox without concomitant immunosuppressive treatment. Partial hematologic responses were observed in 11 of 24 (45.8%) patients; all became transfusion-independent. One patient had an additional platelet response and one patient had an additional platelet and hemoglobin response. Mean serum ferritin levels at end of study were significantly reduced in partial hematologic responders (n=11; −3948±4998 ng/mL; baseline 6693±7014 ng/mL; percentage change from baseline −45.7%; P=0.0029). In non-responders, the reduction in serum ferritin was less pronounced (n=13; −2021±3242 ng/mL; baseline 4365±3063 ng/mL; % change from baseline −27.6%; P=0.0171). Alongside reduction in iron overload, deferasirox may, therefore, improve hematologic parameters in a subset of aplastic anemia patients. Further investigation is required to elucidate the mechanisms involved. (Clinicaltrials.gov identifier: NCT00171821)Keywords
This publication has 22 references indexed in Scilit:
- Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromesHaematologica, 2012
- Positive effects on hematopoiesis in patients with myelodysplastic syndrome receiving deferasirox as oral iron chelation therapy: A brief reviewLeukemia Research, 2011
- Restoration of Hematopoiesis After Iron Chelation Therapy With Deferasirox in 2 Children With Severe Aplastic AnemiaJournal of Pediatric Hematology/Oncology, 2010
- Guidelines for the diagnosis and management of aplastic anaemiaBritish Journal of Haematology, 2009
- Deferasirox Treatment Improved the Hemoglobin Level and Decreased Transfusion Requirements in Four Patients with the Myelodysplastic Syndrome and Primary MyelofibrosisActa Haematologica, 2008
- Iron chelation therapy in the myelodysplastic syndromes and aplastic anemia: a review of experience in South KoreaInternational Journal of Hematology, 2008
- Complete Hematopoietic Recovery after Continuous Iron Chelation Therapy in a Patient with Severe Aplastic Anemia with Secondary HemochromatosisJournal of Korean Medical Science, 2008
- Relative response of patients with myelodysplastic syndromes and other transfusion‐dependent anaemias to deferasirox (ICL670): a 1‐yr prospective studyEuropean Journal of Haematology, 2007
- The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overloadBritish Journal of Haematology, 1996
- Iron Chelators May Enhance Erythropoiesis by Increasing Iron Delivery to Haematopoietic Tissue and Erythropoietin Response in Iron-Loading AnaemiaActa Haematologica, 1993